Condition: Cytokine Release Syndrome · Sponsor: CytoAgents, Inc.
This is an interventional study to evaluate the use of CTO1681 in preventing or reducing CAR T-cell-induced toxicities like cytokine release syndrome (CRS). This study will enroll adult patients with DLBCL who are scheduled to receive CD19-directed CAR T-cell therapy. The first phase of the study will be open label with dose escalation. Participants will start taking CTO1681 just prior to receiving their CAR T-cell therapy and continue to take the study drug three times daily for a total of 15 days.
This description comes directly from the study's public registry record.
Gail Brown, MD · 650-868-2182 · gail@tekteam.net
Heather Nottingham, PhD · heather@tekteam.net
Always discuss trial participation with your own doctor first.
| University of California, Irvine - Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| Georgia Cancer Center at Augusta University | Augusta, Georgia, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Duke Cancer Institute | Durham, North Carolina, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Fred Hutchinson Cancer Center | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05905328